Fresh off the historic but controversial approval of its Alzheimer’s drug Aduhelm with Biogen Inc. in the U.S., Japanese pharmaceutical company Eisai Co. says it’s pushing ahead with its second …
( read original story …)
The Japan News
Fresh off the historic but controversial approval of its Alzheimer’s drug Aduhelm with Biogen Inc. in the U.S., Japanese pharmaceutical company Eisai Co. says it’s pushing ahead with its second …
( read original story …)